Over the past 12 months, 6 insiders at Akero Therapeutics, Inc. filed 26 open-market SEC Form 4 transactions on AKRO: 0 purchases worth $0 and 26 sales worth $8.2M. Insiders have been net sellers over this period. The most recent filing was on Oct 10, 25.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 10, 25 | Andrew ChengPresident and CEO | SELL | 30.0K | $53.98 | $1.6M |
| Oct 7, 25 | Timothy RolphChief Scientific Officer | SELL | 11.5K | $46.82 | $527K |
| Oct 1, 25 | Jonathan YoungChief Operating Officer | SELL | 8.3K | $47.98 | $395K |
| Sep 11, 25 | Timothy RolphChief Scientific Officer | SELL | 553 | $43.02 | $24K |
| Sep 11, 25 | William Richard WhiteChief Financial Officer | SELL | 659 | $43.02 | $28K |
| Sep 11, 25 | Catriona YaleChief Development Officer | SELL | 659 | $43.02 | $28K |
| Sep 11, 25 | Jonathan YoungChief Operating Officer | SELL | 586 | $43.02 | $25K |
| Sep 11, 25 | Andrew ChengPresident and CEO | SELL | 1.8K | $43.02 | $77K |
| Sep 10, 25 | Andrew ChengPresident and CEO | SELL | 22.5K | $44.62 | $968K |
| Sep 8, 25 | Timothy RolphChief Scientific Officer | SELL | 12.5K | $44.88 | $551K |
| Sep 2, 25 | Jonathan YoungChief Operating Officer | SELL | 9.7K | $47.58 | $444K |
| Aug 12, 25 | Jane HendersonDirector | SELL | 3.0K | $47.46 | $142K |
| Aug 12, 25 | Jonathan YoungChief Operating Officer | SELL | 11.2K | $48.32 | $532K |
| Aug 11, 25 | Andrew ChengPresident and CEO | SELL | 18.8K | $49.44 | $919K |
| Aug 5, 25 | Timothy RolphChief Scientific Officer | SELL | 7.0K | $49.49 | $345K |
| Jul 16, 25 | Catriona YaleChief Development Officer | SELL | 8.7K | $53.47 | $458K |
| Jul 10, 25 | Andrew ChengPresident and CEO | SELL | 15.3K | $51.73 | $792K |
| Jul 7, 25 | Timothy RolphChief Scientific Officer | SELL | 10.6K | $52.62 | $542K |
| Jul 1, 25 | Patrick LamySenior VP, Commercial Strategy | SELL | 2.0K | $52.88 | $106K |
| Jun 20, 25 | Patrick LamySenior VP, Commercial Strategy | SELL | 875 | $54.59 | $48K |
| Jun 18, 25 | Andrew ChengPresident and CEO | SELL | 6.6K | $54.84 | $363K |
| Jun 18, 25 | Scott A. GangloffChief Technology Officer | SELL | 848 | $54.84 | $47K |
| Jun 18, 25 | Timothy RolphChief Scientific Officer | SELL | 1.1K | $54.84 | $62K |
| Jun 18, 25 | William Richard WhiteChief Financial Officer | SELL | 1.6K | $54.84 | $90K |
| Jun 18, 25 | Catriona YaleChief Development Officer | SELL | 1.6K | $54.84 | $90K |
| Jun 18, 25 | Jonathan YoungChief Operating Officer | SELL | 1.5K | $54.84 | $80K |
| Jun 16, 25 | Patrick LamySenior VP, Commercial Strategy | SELL | 1.5K | $55.09 | $81K |
| Jun 16, 25 | Catriona YaleChief Development Officer | SELL | 6.2K | $55.52 | $334K |
| Jun 10, 25 | Andrew ChengPresident and CEO | SELL | 15.2K | $54.35 | $824K |
| Jun 10, 25 | Patrick LamySenior VP, Commercial Strategy | SELL | 919 | $54.00 | $50K |
| Jun 10, 25 | Timothy RolphChief Scientific Officer | SELL | 2.4K | $54.00 | $127K |
| Jun 10, 25 | William Richard WhiteChief Financial Officer | SELL | 2.8K | $54.00 | $151K |
| Jun 10, 25 | Catriona YaleChief Development Officer | SELL | 2.8K | $54.00 | $151K |
| Jun 10, 25 | Jonathan YoungChief Operating Officer | SELL | 2.5K | $53.99 | $135K |
| Jun 6, 25 | Timothy RolphChief Scientific Officer | SELL | 25.0K | $55.04 | $1.4M |
| Jun 5, 25 | Timothy RolphChief Scientific Officer | SELL | 9.3K | $53.84 | $499K |
| Jun 2, 25 | Patrick LamySenior VP, Commercial Strategy | SELL | 3.3K | $51.04 | $167K |
| May 22, 25 | Patrick LamySenior VP, Commercial Strategy | SELL | 4.0K | $50.00 | $200K |
| May 15, 25 | Catriona YaleChief Development Officer | SELL | 4.4K | $39.91 | $175K |
| May 12, 25 | Andrew ChengPresident and CEO | SELL | 22.8K | $41.63 | $949K |
| May 7, 25 | Patrick LamySenior VP, Commercial Strategy | SELL | 4.7K | $42.76 | $199K |
| May 6, 25 | Timothy RolphChief Scientific Officer | SELL | 8.7K | $44.50 | $379K |
| Apr 24, 25 | Timothy RolphChief Scientific Officer | SELL | 6.3K | $41.03 | $256K |
| Apr 15, 25 | Catriona YaleChief Development Officer | SELL | 7.9K | $38.62 | $298K |
| Apr 10, 25 | Andrew ChengPresident and CEO | SELL | 30.0K | $35.23 | $1.1M |
| Apr 7, 25 | Timothy RolphChief Scientific Officer | SELL | 3.8K | $37.92 | $135K |
| Mar 27, 25 | G. Walmsley GrahamDirector | BUY | 50.0K | $43.55 | $2.2M |
| Mar 26, 25 | G. Walmsley GrahamDirector | BUY | 58.7K | $43.01 | $2.5M |
| Mar 25, 25 | G. Walmsley GrahamDirector | BUY | 91.3K | $44.75 | $4.1M |
| Mar 17, 25 | Catriona YaleChief Development Officer | SELL | 8.2K | $45.05 | $367K |
Over the past 12 months, insiders at Akero Therapeutics, Inc. filed 0 open-market purchases worth $0 and 26 sales worth $8.2M on AKRO, which makes them net sellers over the period. The most recent Form 4 was filed on Oct 10, 25.
The largest recent open-market AKRO insider purchase in our data was $4.1M by G. Walmsley Graham, Director, filed on Mar 25, 25.
6 different insiders at Akero Therapeutics, Inc. filed open-market SEC Form 4 transactions on AKRO over the last 12 months.
InsiderTape plots every AKRO insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Akero Therapeutics, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →